BPC-157 is one of the most talked-about peptides on the internet. Athletes inject it for tendon and joint injuries, podcast guests credit it with fixing pain that nothing else could touch, and in July 2026 it reached an FDA advisory committee — which voted, narrowly, to make it easier to obtain. Yet the World Anti-Doping Agency has it banned, and the agency's own scientists recommended against it. So what does the evidence on BPC-157 actually show, and why is a compound that supposedly heals everything still banned? The answer runs back fifty years, to a single researcher and a question about the human stomach.
The story starts with a puzzle. The stomach holds acid strong enough to strip meat from bone, yet it does not digest itself. Something protects it. In 1989, after more than a decade of work, a Croatian researcher named Predrag Sikirić isolated a molecule he believed was that protector, and named it BPC-157 [1][2].
Table of Contents
- The Obsession Behind BPC-157
- The Compound That Healed Everything — in Rats
- The Pharma Years and the Buried Trial
- An Orphan Molecule, and the Leap to Injuries
- Why BPC-157 Is Banned
- References
The Obsession Behind BPC-157
In 1975, Sikirić was a second-year medical student at the University of Zagreb, in Croatia — then one of the republics of Yugoslavia. He became fixated on the stomach puzzle and reached a conclusion nobody was teaching him: the stomach must make its own protective, healing substance, some natural compound that keeps it from eating itself alive.
He half-jokingly gave the thing he was hunting a name: "Substance God help me." Finding it took more than a decade — collecting gastric juice, chasing a substance no one was even sure existed. One stubborn idea, against years of nothing. But in 1989, he finally had it.
The Compound That Healed Everything — in Rats
The team's first paper landed in 1992. BPC-157 turned out to be a fragment — the first fifteen amino acids snipped off a much larger protein. A peptide. The initials stand for Body Protection Compound [3].
Then comes the part that makes the story so strange: the group tested that tiny fragment on almost everything. In rats, they triggered stomach ulcers three separate ways — with stress, with a chemical called cysteamine, and with almost pure alcohol — and BPC-157 protected against all three. As the researchers reported, "only BPC 157 regimes were consistently effective in all of the tested models" [4].
Tendons came next. Tendons are notoriously slow to heal because they barely have a blood supply, so it was striking when researchers cut a rat's Achilles tendon clean through, gave it BPC-157, and described a full recovery — "the reestablishment of full tendon integrity." Again, in a rat [5].
Then skin wounds, muscle, bone, even nerve. And the group began working out how it might be doing all this. First, it appeared to calm inflammation: irritating a rat's nose with capsaicin — the compound that makes chilli peppers hot — produced a reaction that BPC-157 blunted, with a "dose-dependent protective effect" [6]. Second, it grew new blood vessels, switching on a growth signal called VEGF and appearing to act through nitric oxide, which controls blood flow [7][8].
For nearly every injury they could think of, BPC-157 seemed to protect and heal. Sikirić's group were so struck that they proposed it might be the first of an entirely new class of medicines — "a useful prototype of a new class of drugs," which they called organoprotective agents [9]. But a compound that heals everything is one of two things: a genuine breakthrough, or a warning sign.
One more early finding is worth holding onto, because it returns later. In 1997, Sikirić's own lab reported that BPC-157 did something in the brain — it blunted the effects of amphetamine, blocking "the stereotypy produced acutely by amphetamine" [10].
The Pharma Years and the Buried Trial
For a while, it looked as though BPC-157 might become a real medicine — because a real drug company thought so too. In 1993, a Croatian pharmaceutical company called PLIVA licensed it and ran a human clinical trial. Because the original research concerned the gut, PLIVA tested it in the bowel disease ulcerative colitis, given as an enema, in a randomized, placebo-controlled study [11].
That trial finished twenty years ago and was never published in full. For two decades, nobody outside the company could see how it had turned out — until 2026, when the FDA put the numbers into a public document. Fifty-three patients, BPC-157 as an enema against placebo for two weeks, and a difference between the groups of just 1.6 points on a disease-activity score, with a confidence interval that crossed zero [12].
In plain terms, the result could just as easily have been nothing at all. The FDA's own summary called the data "inadequate to support the efficacy and safety of BPC-157 given as an enema for two weeks" [12].
Then, in 2006, the pharmaceutical giant GSK bought PLIVA's research arm. The BPC-157 programme was quietly dropped, the rights drifted back to Sikirić, and the compound fell out of the pharmaceutical world entirely. The reason it never came back is not a conspiracy — it is economics.
An Orphan Molecule, and the Leap to Injuries
Patents last twenty years. The patent covering the molecule was filed in 1990, which means it expired in 2011. Once a compound is in the open, nobody can own it — and that cuts both ways. The public can obtain it from grey-market labs, but no company can recoup the cost of a large, expensive human trial, because the moment it was proven to work, every grey-market lab on earth would sell the identical molecule for a fraction of the price, having spent nothing on research. So the trials simply stopped. As a 2026 review noted, the original composition-of-matter patents "have likely expired… reducing the commercial exclusivity that typically incentivizes industry-sponsored Phase II and III development" [13].
To date, there is only one published human study of BPC-157: a retrospective survey of sixteen people who had it injected into a painful knee, with no control group and no placebo, asked months later whether they felt better [14]. Knees improve on their own all the time, so the study tells us almost nothing. The only other human study, from 2015, was abandoned — by 2016 the researchers had cancelled submission of the results [15].
So the science stalled. In the real world, something else happened entirely: bodybuilders and self-experimenters dug up the old rat tendon studies and began injecting BPC-157 into their own shoulders and knees. A drug built for the gut had become a tendon injection.
Here is what the FDA said about that in 2026. It searched for human studies of BPC-157 given by injection, by mouth, as a nasal spray, or through the skin — every route people actually use — and found "no studies that administered BPC-157 to humans via the proposed oral, SC, nasal, or transdermal ROA" [12]. (SC means subcutaneous, i.e. injected.)
To be fair to the idea, the animal work suggested BPC-157 grows new blood vessels, which in theory could mean more blood supply and faster healing — potentially useful for tendons, which have a poor blood supply. But growing new blood vessels is also exactly what a tumour needs to grow. The honest position is that nobody has shown BPC-157 causes cancer, nobody has shown it does not, and nobody has run the experiment. Sikirić has said the risk is "entirely excluded," based on a cell study from 2004 — a statement widely criticised, because the human safety data simply are not there. As one 2025 review put it, "to date, no published in vivo data demonstrate that BPC 157 inhibits tumor progression, reduces tumor volume, or suppresses metastasis" [16].
The 1997 amphetamine finding also resurfaced. People online now report that BPC-157 flattens their mood and dulls their stimulant medication. That signal comes from a data-mining project on Reddit — aggregated anecdote, not evidence, and worth treating with heavy caution. But it points straight at something Sikirić's own lab published nearly thirty years ago.
The deepest gap of all leads back to Sikirić himself. The larger protein that BPC-157 is supposedly a fragment of has never had its full sequence published, in more than thirty years. When independent researchers went looking for the gene that would build it — in the human genome, in gut bacteria — they could not find it. Anna Mapp, a chemist at the University of Michigan and president of the American Peptide Society, reviewed the work and concluded: "There was no demonstration that I could tell that it was a single pure isolated substance" [17][18][19]. Asked by a reporter why he will not release the sequence, Sikirić's answer was telling: "If you have your own child, you want it to be yours forever."
The more ordinary knowledge gaps are large too. Beyond the missing sequence, no one has ever found the receptor BPC-157 is supposed to work through. It clears the bloodstream in under thirty minutes, yet users claim effects lasting days. And there is no pharmaceutical-grade version anywhere in the world — nothing made to a genuine medical standard.
Which brings the story to the FDA vote. Despite headlines suggesting the FDA approved BPC-157, it did not. A panel of outside advisers voted, by a single vote, to recommend that pharmacies be allowed to compound it. The recommendation is non-binding, the FDA has not agreed to it, no rule has been written, and any actual rule is likely a year or more away. The agency's own scientists had already reviewed the data and recommended against it, proposing "not adding BPC-157 (free base) or BPC-157 acetate to the 503A Bulks List" [12].
One FDA official laid out the core problem at the meeting: BPC-157 is not a recognised pharmaceutical ingredient in the United States, and there is no legal definition of what it actually is. Two vials with the same name on the label can contain different things, so the agency cannot even write a quality standard for it — because it cannot say what "it" is. In the words of Russell Wesdyk, associate director in the FDA's drug center: "There's no way to know what the substance actually is, was or will be tomorrow because that name has no legal meaning" [20].
The panel voted anyway. And the only condition they considered it for was ulcerative colitis — the gut, not tendons, not injuries, not the reason almost anyone is buying it. The regulators are still looking exactly where Sikirić pointed fifty years ago, while everyone else is injecting a shoulder or an elbow.
Why BPC-157 Is Banned
So why did the World Anti-Doping Agency ban BPC-157, if there is almost no human evidence that it works? Not because it works. WADA placed it on a list called S0: "Non-Approved Substances" — the category for anything that no health authority anywhere in the world has approved for use in humans. As the anti-doping guidance states, "Because BPC-157 has not been extensively studied in humans, no one knows if there is a safe dose, or if there is any way to use this compound safely" [21].
The ban, in other words, was never proof that BPC-157 works. It is the opposite — an official statement that nobody knows what it does, mirroring the FDA's own position. And the compounding list the panel voted for exists, by law, specifically for substances that are not approved. Getting onto it is not an approval; it is the formal acknowledgement that the substance never received one.
That is the whole story, start to finish: a stubborn idea from 1975, a researcher who spent his life on it, a compound that healed everything in rats, a human trial whose result nobody saw for twenty years, a molecule no company can own so no company will finish testing, and a stack of the most basic questions — is it safe, at what dose, made by whom, and how does it actually work — that still have no answers.
The honest bottom line is that the evidence for BPC-157 is not there yet — not that it has been disproven, but that it has never been properly tested in people at all. What anyone chooses to do with that is a personal decision, ideally made with a doctor who knows the full picture.
References
1. https://youtu.be/KN91N_VoowU
3. https://patents.google.com/patent/US5288708A
4. https://www.sciencedirect.com/science/article/abs/pii/0024320594007969
5. https://onlinelibrary.wiley.com/doi/10.1016/S0736-0266(03)00110-4
6. https://pubmed.ncbi.nlm.nih.gov/9065615/
7. https://pubmed.ncbi.nlm.nih.gov/20388964/
8. https://www.eurekaselect.com/article/52839
9. https://www.sciencedirect.com/science/article/abs/pii/092842579390038U
10. https://doi.org/10.1016/S0006-3223(97)00277-1
11. https://cir.nii.ac.jp/crid/1573105975523152000
12. https://www.fda.gov/media/193343/download
13. https://www.mdpi.com/1999-4923/18/5/625
14. https://pubmed.ncbi.nlm.nih.gov/34324435/
15. https://doi.org/10.3390/ph18020185
16. https://doi.org/10.3390/ph18101451
17. https://undark.org/2026/05/29/stress-test-bpc-157-history/
18. https://www.statnews.com/2026/06/01/bpc-157-researcher-predrag-sikiric-addesses-skeptics-questions/
19. https://americanpeptidesociety.org/news/the-bpc-157-question/
21. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
